Blocking Stress Hormone Receptors Changed Multiple Opioid and Reproductive Peptides
Blocking CRF receptors reduced beta-endorphin and enkephalin but increased dynorphin and reproductive hormone LHRH — showing these systems are tightly linked.
Quick Facts
What This Study Found
Alpha-helical CRF9-41 (a CRF receptor blocker) applied to hypothalamic slices in vitro caused beta-endorphin and met-enkephalin to drop significantly within 10 minutes. At the same time, LHRH (luteinizing hormone-releasing hormone) rose significantly.
Dynorphin also decreased but the change was not statistically significant.
When the antagonist was removed, the pattern reversed within 10 minutes: beta-endorphin, met-enkephalin, and dynorphin rose back up while LHRH fell back down.
The same results were obtained in vivo using push-pull perfusion of the arcuate-median eminence region in anesthetized rats. This confirmed the in vitro findings in living animals.
Key Numbers
How They Did This
In vitro: hypothalamic slices perifused with CRF antagonist. In vivo: push-pull perfusion of the arcuate-median eminence in chloral hydrate-anesthetized rats. All four peptides measured simultaneously in each sample by radioimmunoassay.
Why This Research Matters
This study proved that the CRF-opioid-LHRH pathway operates in both isolated tissue and living animals. The reciprocal relationship (opioids down = LHRH up) and rapid timing (10 minutes) show this is a tightly regulated system. It explains how stress suppresses reproduction at the neuroendocrine level.
The Bigger Picture
This explains a major mechanism of how stress suppresses reproduction: CRF activates opioid peptides that then inhibit reproductive hormone release. Blocking CRF reverses this cascade.
What This Study Doesn't Tell Us
In vivo experiments used anesthetized rats, which may alter neuroendocrine function. Only one concentration of the CRF antagonist was tested. The study did not identify which specific CRF receptor subtype is involved.
Questions This Raises
- ?Could CRF antagonists treat stress-related infertility?
- ?Does chronic stress permanently alter this opioid-reproductive axis?
Trust & Context
- Key Stat:
- Opposite opioid changes CRF blockade decreased endorphin/enkephalin but increased dynorphin
- Evidence Grade:
- Preliminary animal study with good in vitro/in vivo concordance.
- Study Age:
- Published in 1988 — key finding linking stress, opioids, and reproductive function.
- Original Title:
- Concomitant changes in the in vitro and in vivo release of opioid peptides and luteinizing hormone-releasing hormone from the hypothalamus following blockade of receptors for corticotropin-releasing factor.
- Published In:
- Neuroendocrinology, 47(6), 545-50 (1988)
- Authors:
- Nikolarakis, K E(4), Almeida, O F(5), Sirinathsinghji, D J, Herz, A
- Database ID:
- RPEP-00083
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
How does stress suppress fertility?
Stress increases CRF, which activates opioid peptides (especially beta-endorphin) that then inhibit GnRH/LHRH release. Without this reproductive hormone signal, ovulation and testosterone production decline.
Could reducing stress hormones improve fertility?
This study suggests yes — blocking CRF receptors increased reproductive hormone release. Stress management and potential future CRF-targeting drugs could help restore fertility.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00083APA
Nikolarakis, K E; Almeida, O F; Sirinathsinghji, D J; Herz, A. (1988). Concomitant changes in the in vitro and in vivo release of opioid peptides and luteinizing hormone-releasing hormone from the hypothalamus following blockade of receptors for corticotropin-releasing factor.. Neuroendocrinology, 47(6), 545-50.
MLA
Nikolarakis, K E, et al. "Concomitant changes in the in vitro and in vivo release of opioid peptides and luteinizing hormone-releasing hormone from the hypothalamus following blockade of receptors for corticotropin-releasing factor.." Neuroendocrinology, 1988.
RethinkPeptides
RethinkPeptides Research Database. "Concomitant changes in the in vitro and in vivo release of o..." RPEP-00083. Retrieved from https://rethinkpeptides.com/research/nikolarakis-1988-concomitant-changes-in-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.